The ATEMPT trial compared adjuvant treatment in HER2-positive breast cancer with paclitaxel plus trastuzumab versus TDM-1 (ado-trastuzumab emtansine, an antibody–drug conjugant). Here, ERBB2 is linked to breast cancer.